Log In
Print this Print this

Atripla, emtricitabine/tenofovir/efavirenz

Also known as: Viread/Sustiva/Emtriva

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionOnce-daily combination tablet of Truvada emtricitabine/tenofovir and BMY's Sustiva efavirenz
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection
Regulatory Designation
Partner Bristol-Myers Squibb Co.; Merck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today